Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.73 |
| ▸ | BTK | Q06187 | 2/20 | 0.69 |
| ▸ | STK3 | Q13188 | 8/20 | 0.68 |
| ▸ | STK4 | Q13043 | 6/20 | 0.67 |
| ▸ | STK25 | O00506 | 1/20 | 0.66 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.66 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.66 |
| ▸ | STK17B | O94768 | 1/20 | 0.66 |
| ▸ | STK10 | O94804 | 1/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943741 | 0.95 | EGFR (0.79) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL3600093 | 0.94 | EGFR (0.69) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL3602540 | 0.94 | EGFR (0.69) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL9911521 | 0.93 | EGFR (0.63) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL2948351 | 0.93 | EGFR (0.74) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL3595623 | 0.91 | EGFR (0.67) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL14854794 | 0.91 | EGFR (0.63) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL2949647 | 0.90 | EGFR (0.74) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL3598492 | 0.90 | EGFR (0.77) | EGFRERBB2SRCKDRBTK | |
| SCHEMBL3600983 | 0.90 | EGFR (0.67) | EGFRERBB2SRCKDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | claimed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | claimed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885ERBB2 199/4885SRC 355/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885SRC 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.